CLN12 is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multiple systems. Early identification and standardization of clinical trials are essential for improving prognosis. Diagnosis of CLN12 requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help to combine teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of CLN12 requires individualized development of multiple treatment programs, typically including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult to treat genetic metabolic disorders.
Treatment requires close monitoring of therapeutic effects and adverse reactions, adapting to timely schemes depending on the changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of CLN12. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.